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Abstract  
Type 2 Diabetes Mellitus (T2DM) is highly predictive of cardiovascular diseases and is associated with 
worse quality of life and increased healthcare utilisation. The current meta-analysis aimed to (i) 
describe the pooled prevalence of T2DM in people with alcohol use disorders (AUDs), (ii) investigate 
the impact of demographic, clinical and treatment factors, and (iii) compare T2DM prevalences in 
AUDs versus the general population. The trim and fill adjusted pooled T2DM prevalence among 3,998 
people with AUDs (age range 34.8 to 51.1 years; 76.6% male) (N studies=7) was 12.4% 
(95%CI=11.8%-13.9%). Higher T2DM prevalences were observed in studies with a higher mean age 
and a higher percentage of male participants, and in studies with self- or physician reported T2DM 
assessment. A trend for higher T2DM prevalences was found in inpatient settings, in studies 
assessing T2DM with the gold-standard oral glucose tolerance test compared with fasting glucose 
only, and with studies including patients with a higher percentage of physical co-morbidity. Although 
healthy control data are lacking, the pooled prevalence is similar to that observed in people with 
severe mental illness who are considered a high-risk group. Routine screening and multidisciplinary 
management of T2DM in people with AUDs is needed.  
 
Introduction 
In general population surveys people with alcohol use disorders (AUDs) experience an excess 
mortality rate two times higher than those without AUDs (Roerecke and Rehm, 2013). Compared with 
the general population, people with AUD have more than a 10-fold risk of mortality from liver cirrhosis, 
a seven-fold risk for injury fatalities and a two-fold risk for cardiovascular and cancer deaths (Roerecke 
and Rehm, 2014).   
Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular diseases. It confers 
about a two-fold excess risk for coronary heart disease, major stroke subtypes, and deaths attributed 
to other vascular causes (Collaboration, 2010). Major risk factors for T2DM in people with AUDs 
include the high risk for acute pancreatitis (Das et al., 2013), unhealthy lifestyle behaviors such as lack 
of sufficient physical activity (Smothers and Bertolucci, 2001), co-morbid substance abuse (McKee et 
al., 2007) in particular smoking (Goodwin et al., 2013) and an impaired cardiorespiratory fitness 
(Herbsleb et al., 2013). Once developed, patients with AUDs have a severely impaired diabetes self-
management and worse health outcomes (Thomas et al., 2012). Prevention and treatment of T2DM 
therefore demands careful consideration in clinical practice, and particularly in those with an increased 
risk for cardiovascular diseases and associated premature mortality (Alberti and Zimmet, 1998). 
Several reviews on alcoholism and T2DM indicated that chronic heavy consumption deteriorates 
glucose tolerance and insulin resistance, and this may well be one of the mechanisms involved in the 
malignant effect of alcohol, with regard to development of T2DM (Conigrave and Rimm, 2003; Howard 
et al., 2004; Kim and Kim, 2012; Li et al., 2016; Molina et al., 2014).  
However, meta-analytic data considering the prevalence of T2DM and its moderators are 
currently lacking in the literature. Pooling T2DM prevalence data in people with AUDs allows for 
investigation of the effect of demographic variables (e.g., age, gender, illness duration), clinical (e.g., 
% psychiatric co-morbidity, % physical co-morbidity, % smoking) and treatment (e.g., psychotropic 
medication use) related factors. If risk stratification is observed, this could potentially help guide 
clinicians in monitoring and treating high-risk individuals. Given the aforementioned gap within the 
literature, we conducted a systematic review and meta-analysis of pooled T2DM prevalences in 
people with AUDs. We aimed to (i) describe pooled T2DM frequencies in AUDs, (ii) analyze the 
influence of demographic, clinical and treatment variables as well as T2DM assessment methods, and 
(iii) compare T2DM prevalence in studies directly comparing people with AUD with general population 
samples. 
 
Methods 
This systematic review was conducted in accordance with the MOOSE guidelines  (Stroup et al., 
2000) and in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) standard (Moher et al., 2009). 
Inclusion and exclusion criteria 
Included were: (1) observational studies (cross-sectional, retrospective and prospective studies) and 
baseline data of randomized controlled trials; (2) studies involving adults with a standardized primary 
diagnosis of alcohol use disorder, alcohol dependence, harmful alcohol use, alcohol abuse as 
diagnosed by the DSM-IV (American Psychiatric Association, 1994), DSM 5 (American Psychiatric 
Association, 2013) or the International Classification of Disease (WHO, 1993) or an Alcohol Use 
Disorders Identification Test (AUDIT) score of ≥15 (i.e. likely severe alcohol problem) (Babor et al., 
2001), irrespective of clinical setting (inpatient, outpatient or mixed) and, (3) studies that reported 
study-defined T2DM prevalences. We excluded: (1) case reports, (2) conference abstracts, and (3) 
studies restricted to patients with cardiometabolic diseases or excluding at risk patients. When 
required, we contacted the primary or corresponding authors of studies up to two times in a one-month 
period to (1) confirm eligibility, and (2) obtain the data required for analysis if they were not available in 
the published paper.   
 
Search criteria, study selection and critical appraisal 
Two independent authors (DV, BS) searched Medline, PsycARTICLES, Embase and CINAHL from 
database inception to March1
st
, 2015 without language restrictions. Key words used were “diabetes” 
or “glucose” or “hyperglycemia” AND “alcohol dependence” OR “alcohol abuse” OR “alcohol misuse” 
OR “harmful alcohol use” OR “alcohol use disorders” in the title, abstract or index term fields. Manual 
searches were also conducted using the reference lists from recovered articles. After the removal of 
duplicates, reviewers screened the titles and abstracts of all potentially eligible articles. Both authors 
applied the eligibility criteria, and a list of full text articles was developed through consensus. The two 
reviewers then considered the full texts of these articles and the final list of included articles was 
reached through consensus. A third reviewer (MDH) was available for mediation throughout this 
process. Methodological appraisal was performed according to PRISMA standards (Moher et al., 
2009), including evaluation of bias (confounding, overlapping data, publication bias). Publication bias 
was tested using the Egger’s regression method (Egger et al., 1997) and Begg-Mazumdar test (Begg 
and Mazumdar, 1994) , with a p-value <0.05 suggesting the presence of bias.  
 
Statistical analyses 
We pooled individual study data using the DerSimonian-Laird proportion method with StatsDirect 
(DerSimonian and Laird, 1986). The trim-and-fill approach (Duval and Tweedie, 2000) was used to 
adjust the overall estimate for funnel plot asymmetry. Due to anticipated heterogeneity, a random 
effects meta-analysis was employed. Heterogeneity was measured with the Q statistic, yielding a chi-
square p-value with p<0.05 indicating significant heterogeneity of the pooled results. If available, we 
compared the prevalence of T2DM between people with AUDs and general population control groups 
with AUD that were matched on age and sex, only using data from studies in which they were directly 
compared. Furthermore, in the entire dataset, we conducted subgroup analyses to investigate gender 
differences, differences across settings (inpatients, outpatients or community patients, mixed), 
geographical regions, differences between population and non-population based studies, and between 
methods of T2DM assessment (fasting glucose testing, OGTT, self- or physician report, charts). 
Further, we conducted meta-regression analyses to investigate potential moderators [age, percentage 
male, illness duration, smoking (%), physical inactivity (%), employment status (% employed), marital 
status (% single), % psychiatric co-morbidity (DSM or ICD), % physical co-morbidity (ICD)] and 
treatment-factors (% on psychotropic medication) with Comprehensive Meta Analysis (version 3). The 
significance level was set at P≤0.05. 
 
Results 
Search results and included participants 
After excluding duplicates and irrevelant hits, our search yielded 31 potential publications of which 7 
(including 9 T2DM prevalences) (Chandini and Mathai, 2013; David et al., 2004; Glaus et al., 2013; 
Hong et al., 2015; Ju et al., 2011; Odlaug et al., 2015; Pach et al., 2013) met the inclusion criteria 
(Figure 1). All included studies adopted a cross-sectional design. While in 2 studies T2DM was 
diagnosed according to the gold-standard oral glucose intolerance test (OGTT), 5 studies assessed 
T2DM following fasting glucose assessment and 2 studies relied on self- or physican reports. The final 
sample comprised 3,998 unique persons with AUDs but no matched controls. Sample sizes ranged 
from 88 to 1,660 participants with a median sample size of 173. At study level, the mean age of 
participants with AUD ranged from 34.8 to 51.1 years, 76.6% were male, and mean illness duration (N 
studies=3) was 16.2 years (range=10.6-26.6 years). More details of the included studies and 
participants are presented in Table 1. 
 
Prevalence of T2DM  
The estimated weighted mean prevalence of T2DM among 3,998 people with AUDs was 11.9% 
(95%CI= 9.3% to 15.1%; Q=40.9, p<0.001). The Begg-Mazumdar (Kendall's tau=-0.08, p=0.75) and 
Egger test (bias=-0.63; 95%CI=-03.88 to 2.62; p=0.066) indicated no strong evidence for the presence 
of publication bias. Applying the trim and fill method and adjusting for 2 studies, the prevalence of 
T2DM slightly increased to 12.4% (95%CI=11.8% to 13.9%).   
 
Subgroup analyses and predictors of T2DM  
The pooled prevalences across different treatment settings (inpatients, outpatients, community 
patients, mixed settings), and population versus non-population based), methods of T2DM 
assessment (fasting glucose testing, OGTT, self- or physician report, charts) are summarized in Table 
1. The separate meta-regressions are presented in Table 2. There were no significant overall 
differences between different treatment settings although when directly comparing the pooled T2DM 
between inpatient (16.1%; 95%CI=9.6%-25.8%) and community settings (7.0%; 95%CI=3.4%-13.9%), 
a trend level of significance was observed of higher prevalence in inpatient studies (P=0.09). The 
pooled T2DM prevalence in population-based studies (9.9%; 95%CI=7.5%-12.9%) was significantly 
(P=0.015) lower than in clinical-based (non-population, 17.2%; 95%CI=12.0%-24.0%) studies. A lower 
T2DM prevalence was observed in studies relying upon clinical data gleaned from fasting gmlucose 
(8.5%; 95%CI=5.7%-12.4%) versus self-report studies (16.9%; 95%CI=10.2%-26.7%) (P=0.02). There 
was also a trend for a lower T2DM prevalence when using fasting glucose instead of the gold-
standard OGTT. Also pooled T2DM prevalences per geographical region are displayed in Table 1. No 
significant geographical differences were observed.   
Separate meta-regression analyses (see Table 3 for β values and 95% CI) revealed that 
higher T2DM frequencies were moderated by older age (years) (P=0.015), a higher proportion of 
males (% male) (P=0.003), while there was a trend (P=0.103) for higher % physical co-morbidity.  
 
Relative risk of T2DM in persons with AUD compared with general population controls 
There were no data available comparing the T2DM prevalence of people with AUD versus age- and 
gender matched controls. 
Discussion 
General findings 
To the authors’ knowledge, this is the first meta-analysis of T2DM in people with AUDs. Approximately 
one in 8 individuals with AUDs has T2DM, i.e 12.4% (95%CI=11.8% to 13.9%). When restricting the 
pooled T2DM prevalence to population-based studies the prevalence was one in 10 or 9.9% 
(95%CI=7.5%-12.9%), which might be a more accurate prevalence. The T2DM prevalence rate 
observed in people with AUDs is similar to the T2DM prevalence observed in people with severe 
mental illness (11.3%, 95%CI=10.0% to 12.6%), which was double the relative risk for T2DM found in 
a matched background general population (Vancampfort et al., 2016). Rigorous meta-analytic data 
comparing the T2DM prevalence in people with AUDs versus age- and gender matched healthy 
controls are currently absent. However, in a recent large-scale (n=21,616) survey in a middle-age and 
elderly population, both women [odds ratio (OR)=1.32; 95% CI=1.05-1.65, p<0.05], and men 
(OR=1.84; 95% CI = 1.45-2.33, p<0.01) with past history of AUDs had an increased risk for diabetes 
than those without a history of AUDs (Udo et al., 2015). As the T2DM risk seems to be increased 
compared with general population data and the prevalence observed is comparable with those of 
people with severe mental illness, who are considered an important high risk group (Stubbs et al., 
2015; Vancampfort et al., 2015a; Vancampfort et al., 2015b), investigating demographical, clinical and 
treatment-related factors that could influence T2DM frequency is needed.  
Knowledge of factors associated with a high T2DM risk can also help identify individuals at 
greatest need for intensive monitoring and intervention. Due to lack of data we were not able to 
explore whether illness duration, smoking (%), physical inactivity (%), employment status (% 
employed), marital status (% single), % psychiatric co-morbidity (DSM or ICD), % physical co-
morbidity (ICD) and treatment-related factors (% on psychotropic medication) moderated the pooled 
T2DM prevalence. As observed previously in people with severe mental illness (Vancampfort et al., 
2015b)  increasing age increases the risk for T2DM. In contrast to people with severe mental illness 
(Vancampfort et al., 2016), we however found that men with AUDs had a higher risk for developing 
T2DM than women. Several factors, including hormonal effects and less statistical power due to a 
lower number of women included, may have contributed to these gender differences. Future research 
should explore wether endogenous sex hormones which are reported to modulate glycemic status and 
risk of T2DM differentially in men and women could clarify the lower T2DM prevalence in women with 
AUDs (Ding et al., 2006). For example, cross-sectional and prospective studies found that sex-
hormone-binding-globulin (SHBG) is more protective in women than in men (P≤0.01 for sex difference 
for both), with prospective studies indicating that women with higher SHBG levels (>60 vs ≤60 nmol/L) 
had an 80% lower risk of type 2 diabetes (RR, 0.20; 95% CI, 0.12 to 0.30), while men with higher 
SHBG levels (>28.3 vs ≤28.3 nmol/L) had a 52% lower risk (RR, 0.48; 95% CI, 0.33 to 0.69) (Ding et 
al., 2006). Previous research demonstrated that alcohol intake might lower SHBG levels (Thaler et al., 
2015).  
Finally, patient of physician self-report yielded numerically the highest T2DM prevalences 
followed by data based on OGTT assessment. The higher T2DM prevalence in self-report studies is 
likely due to the fact that in these studies patients were followed a longer period by the reporting 
physician extending the detection period. Unfortunately, due to lack of data we could not explore 
T2DM prevalence differences between cross-sectional and restrospective studies in order to confirm 
this hypothesis.   
 
Clinical implications 
Considering the high T2DM prevalence observed, screening for and trying to minimize risk factors  
should be key in the multidisciplinary treatment of people with AUDs. More specifically, people with 
AUDs should be considered as a clinical population that needs proactive screening for T2DM. It is 
particularly important to establish baseline T2DM risk at initial presentation so that any subsequent 
change during treatment can be monitored. The medical history and examination should, at a 
minimum, include: (a) history of previous cardiovascular diseases, T2DM or other related diseases, (b) 
family history of premature cardiovascular diseases, T2DM or other related diseases, (c) smoking, 
dietary and physical activity habits, (d) weight and height in order to calculate body mass index (BMI), 
and waist circumference, (e) fasting blood glucose and/or hemoglobin A1c (HBA1c) if services and/or 
facilities are available, (f) blood pressure (measured twice and average taken), and (g) past 
medication history (De Hert et al., 2011). As there are differences in T2DM prevalences across T2DM 
assessment methods, it is recommended that ideally data based on oral glucose tolerance testing as 
the gold-standard are obtained. The frequency of glucose metabolism testing will depend on the 
patient’s medical history, the prevalence of baseline risk factors and in less developed countries the 
facilities available. For those with normal baseline tests, it is recommended that measurements should 
be repeated at least annually with more frequent assessments in high risk patients, such as those with 
significant weight gain, post-partum diabetes or a first degree family history of diabetes. In patients 
with T2DM (and those with pre-diabetes), fasting blood glucose and HBA1c should be measured more 
frequently (approximately every 3–6 months) (De Hert et al., 2011). An annual examination should at a 
minimum include measurement of cardiovascular risk factors, an eye examination and foot 
examination to diagnose early signs of complications (De Hert et al., 2011). 
Despite the imperative to screen for T2DM, screening for T2DM and cardiovascular risk 
factors is still suboptimal in mental health care settings with only slight improvement over the last 
decade (De Hert et al., 2011). The low glucose screening rates may reflect both patient and 
professional barriers. Professional barriers to screening within mental health settings may reflect a 
lack of clarity regarding clinical responsibility for the screening process, lack of understanding about 
what should be measured and when, uncertainity about how to interprete results, and lack of access 
to necessary equipment, as well as incomplete communication between primary and secondary care 
(De Hert et al., 2011). Without systematic screening using acceptable and accurate diagnostic tests, 
the true prevalence of T2DM in patients with AUDs will remain unknown. Even after an established 
diagnosis of T2DM is made, many people with AUDs are not offered timely treatment. Thus, routine 
screening is only the first step. Psychiatric centers should cooperate with diabetes experts to establish 
shared care pathways and ensure an integrated approach for people with AUD and T2DM.  
 
Limitations  
Whilst this is the most comprehensive meta-analysis of T2DM in people with AUDs conducted to date, 
we acknowledge several limitations that are largely reflected by factors in the primary data. First, a 
threat to the validity of any meta-analysis is publication bias and heterogeneity, which we encountered 
in most of our analyses.  Nevertheless, we adjusted for publication bias using the trim and fill analysis 
and were able to explain over half of the between study heterogeneity in our multivariable meta-
regression analysis. Second, there were inadequate data on lifestyle behaviors, concomitant somatic 
and psychotropic medication use, smoking rates, physical inactivity, marital and employment status 
precluding meta-analytic assessment of these factors as moderating or mediating variables. Third, 
rigorous data comparing the risk for T2DM in people with AUDs with age- and gender-matched 
healthy controls in large-scale studies are currently missing. Despite the abovementioned caveats, this 
is the largest study of T2DM risk in people with AUD and the first meta-analysis pooling all available 
data. 
 
Future research 
First, the pathophysiology underlying the association between AUDs and T2DM is complex and not 
well understood, requiring further investigation. Previous studies exploring the associations between 
alcohol use and cardiovascular risk factors (Fernández-Solà, 2015) including T2DM (Conigrave and 
Rimm, 2003), have resulted in inconsistent associations. This could be due to the fact that the dose–
response relationship between alcohol and metabolic health has been reported to follow a J- or U-
shaped curve, pointing to lower all-cause mortality among light to moderate drinkers compared to 
heavy drinkers (Fernández-Solà, 2015). Any potentially beneficial effect is apparent only at low to 
modest use (Mostofsky et al., 2016). However, this epidemiological evidence has also been criticized 
due to misclassification and confounding (Chikritzhs et al., 2015). Using Mendelian randomisation 
analysis of 56 epidemiological studies (n=261,991), it was reported recently that reductions in alcohol 
consumption, even for light to moderate drinkers, is beneficial for cardiovascular health (Holmes et al., 
2014; Stockwell et al., 2016). In order to better understand the T2DM risk in people with AUD more 
cross-sectional and in particular longitudinal studies are needed to compare the risk with well-matched 
healthy controls. Second, future research should comprehensively assess T2DM risk factors following, 
at the very least, recommended monitoring guidelines and evaluate the optimal monitoring regimen 
and interventions. Third, long-term follow-up is required to accurately document the emergence of 
more distal outcomes, such as ischemic heart disease, medical costs, and premature mortality (52).  
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Table 1. Details of the included studies 
First Author 
(year) 
Country Participants T2DM 
assessment 
T2DM 
prevalence 
T2DM 
prevalence 
Controls* 
David 2004 USA 38 male Veterans with DSM-IV 
alcohol dependence; 48.3±8.0 years; 
18% employed; 55% major 
depressive disorder; 26.6±9.0 alcohol 
abuse-years 
fasting 
glucose 
8.0% / 
Ju 2011 South-Korea 118 male inpatients with DSM-IV 
alcohol dependence; 49.1±0.9 years; 
11.4 years problematic drinking 
OGTT 22.0% / 
Chandini 2013 India 100 inpatients with ICD-10 alcohol 
dependence; 88% employed; 65% 
physical co-morbidity 
physician 
report based 
on laboratory 
screening 
23.0% / 
Glaus 2013 Switzerland 264 (42♀) community patients with 
DSM-IV alcohol abuse; 50.1±8.7 
years 
  
173 (46♀) community patients with 
DSM-IV alcohol dependence; 
51.1±8.2 years 
 
fasting 
glucose 
 
 
fasting 
glucose  
10.2% 
 
 
 
9.2% 
/ 
 
 
 
/ 
Pach 2014 Czech 
Republic 
88 male inpatients with ICD-10 
alcohol dependence; 39.2±7.8 years; 
illness duration=10.6 ±7.8years  
OGTT 10.2% / 
Hong 2015 South-Korea 1,318 male community participants 
with AUDIT-score≥15; 45.1±0.4 
years; 50.1% physical co-morbidity; 
48.7% physically inactive; 77.3% 
smoking 
 
 239 female community participants 
fasting 
glucose 
 
 
 
 
fasting 
11.2% 
 
 
 
 
 
3.5% 
/ 
 
 
 
 
 
/ 
In
c
lu
d
e
d
 
E
lig
ib
ili
ty
 
Records excluded  
(N=8) 
Reasons: case reports 
(N=4), review (N=2), 
conference abstracts 
(N=2) 
Full-text articles assessed 
for eligibility  
(N=23) 
Excluded full-text articles 
(N=16) 
Reasons: no standardized 
AUD criteria (N=4), no 
prevalence rates obtained 
(N=3), incidence rate 
(N=3), no prevalence rates 
available (N=2), only 
patients with diabetes 
included (N=1), diabetes 
was an exclusion criterion 
(N=1), overlap (N=1), AUD 
not primary diagnosis 
(N=1) 
Studies included in 
qualitative synthesis  
(N=7) 
with AUDIT-score≥15; 45.1±0.4 
years; 51.5% physical co-morbidity; 
54.5% physically inactive; 11.6% 
smoking 
glucose 
Odlaug 2015 Europe  
(8 countries) 
1660 (523♀) participants in mixed 
settings; 48.3±12.6 years; 26.5% 
single status; 43.1% major depressive 
disorder; 64% psychiatric co-
morbidity; 50% physical co-morbidity 
physician 
report 
13.2% / 
OGTT= Oral Glucose Tolerance Test; AUDIT= Alcohol Use Disorders Identification Test 
 
 
 
Table 2. Subgroup analyses of moderators of type 2 diabetes in people with alcohol use disorders 
 
Analysis Meta-analysis Heterogeneity 
 Number of 
comparisons 
Effect size 95% CI Between 
group 
difference 
p-value 
I
2
 Q p-value 
Population based or not 
     Population based 
     Non-population based 
 
4 
5 
 
9.9% 
17.2% 
 
7.5%-12.9% 
12.0%-24.0% 
0.015 80.4 40.9 <0.001 
Study setting 
     Mixed settings 
     Inpatient settings 
     Outpatient settings 
     Community settings 
 
1 
4 
2 
2 
 
13.2% 
16.1% 
9.9% 
7.0% 
 
5.4%-28.9% 
9.6%-25.8% 
4.9%-19.1% 
3.4%-13.9% 
0.27 80.4 40.9 <0.001 
Diabetes assessment method 
     Fasting glucose 
     Oral glucose tolerance test 
     Self- or physician report 
 
5 
2 
2 
 
18.5% 
16.1% 
16.9% 
 
5.7%-12.4% 
9.0%-27.3% 
10.2%-26.7% 
0.05 80.4 40.9 <0.001 
Geographical region    0.73 80.4 40.9 <0.001 
     North-America 1 7.9% 1.9%-27.6%     
     Europe 4 10.9% 6.8%-16.9%     
     Asia 4 12.9% 8.2%-19.9%     
 
 
Table 3.  Meta-regressions of moderators of type 2 diabetes in people with alcohol use disorders 
Moderator Number of 
comparisons 
       β 95% CI   p-
value 
R² 
Mean age (years) 8 0.07 0.01 to 0.12 0.015 0.60 
Gender (% male) 9 1.34 0.44 to 2.24  0.003 0.66 
Physical co-morbidity (%) 4 6.8 -1.39 to 15.0 0.104 0.49 
 
 
Highlights 
 Approximately one in 8 individuals with alcohol use disorders has diabetes.  
 Older age and male gender are risk factors for diabetes in alcohol use disorders.  
 People with alcohol use disorders have a comparable diabetes risk than those with severe 
mental illness. 
 Routine screening for diabetes is needed in those with alcohol use disorders. 
 
